Significant Weight Loss With Controlled-Release Phentermine/Topiramate (PHEN/TPM CR) Is Associated With Significant Reductions in Use of Concomitant Medications For Cardiometabolic Diseases Over 108 Weeks

被引：0

作者：

Garvey, W. Timothy

Najarian, Thomas

Peterson, Craig A.

机构：

来源：

OBESITY | 2011年 / 19卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：S176 / S176

页数：1

共 31 条

[1] Weight Loss (WL) and Change in Antidiabetic Medications Over 2 Years With Controlled-Release Phentermine/ Topiramate (PHEN/TPM CR)
Kushner, Robert F.
Troupin, Barbara
DIABETES, 2012, 61 : A507 - A507
[2] Once-daily, controlled-release phentermine/topiramate (PHEN/TPM CR) results in significant weight loss and risk factor improvement in overweight/obese subjects over 56 weeks
Aronne, L. J.
Troupin, B.
Day, W. W.
DIABETES OBESITY & METABOLISM, 2010, 12 : 51 - 52
[3] Amount of cardiometabolic risk reduction is directly associated with magnitude of weight loss with low-dose, controlled-release phentermine/topiramate (PHEN/TPM CR)
Klein, S.
Tam, P.
Peterson, C.
DIABETES OBESITY & METABOLISM, 2010, 12 : 52 - 52
[4] Weight Loss with Controlled-Release Phentermine/Topiramate (PHEN/TPM CR) Reverses Metabolic Syndrome (MetS) and Improves Associated Traits
Garvey, W. Timothy
Henry, Robert R.
Peterson, Craig A.
Bowden, Charles H.
DIABETES, 2011, 60 : A506 - A506
[5] MAGNITUDE OF WEIGHT LOSS CONFERRED BY CONTROLLED-RELEASE LOW-DOSE PHENTERMINE/TOPIRAMATE (PHEN/TPM CR) DETERMINES EXTENT OF CARDIOMETABOLIC BENEFIT.
Troupin, B.
Hankin, C. S.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S38 - S39
[6] Severely Obese Adults Administered Controlled-Release Phentermine/Topiramate (PHEN/TPM CR) Maintained Their Weight Loss in the Second Year
Gadde, Kishore M.
Allison, David B.
Tam, Peter
Troupin, Barbara
OBESITY, 2011, 19 : S176 - S176
[7] Improved Cardiometabolic Risk Factors in Overweight/Obese Subjects Receiving Controlled-Release Phentermine/Topiramate (PHEN/TPM CR)
Cheskin, Lawrence J.
Peterson, Craig A.
DIABETES, 2012, 61 : A710 - A710
[8] Diabetes Prevention in Subjects With Prediabetes Using Controlled-Release Phentermine/Topiramate (PHEN/TPM CR) Over 2 Years
Garvey, W. T.
Bowden, Charles H.
DIABETES, 2012, 61 : A517 - A517
[9] Long-Term Weight Loss and Improvement in Glycemic Parameters with Low-Dose, Controlled-Release Phentermine/Topiramate (PHEN/TPM CR)
Kushner, Robert F.
Garvey, W. Timothy
Troupin, Barbara
Day, Wesley W.
DIABETES, 2011, 60 : A515 - A515
[10] Magnitude of Weight Loss Experienced with a Low-Dose, Controlled-Release Formulation of Phentermine/Topiramate (PHEN/TPM) May Drive Degree of Cardiometabolic Benefit
Gadde, Kishore
Najarian, Thomas
Day, Wesley W.
DIABETES, 2010, 59 : A482 - A483

← 1 2 3 4 →